离子导入地塞米松磷酸盐与局部醋酸泼尼松龙1%治疗非感染性前节葡萄膜炎的比较
这项前瞻性随机双盲平行组非劣效试验纳入193例活动性非感染性前节葡萄膜炎患者,比较经巩膜离子导入地塞米松磷酸盐(EGP-437)与局部醋酸泼尼松龙1%的疗效与安全性。第14天前房细胞数为零的比例两组相近(33.3% vs 33.0%),但未达到统计非劣效;EGP-437组眼压升高≥6 mm Hg的事件数较少。
要点
- 第14天前房细胞清零率EGP-437组33.3%(32/96)与PA 1%组33.0%(32/97)相近,但非劣效未成立。
- 基线前房细胞计数>25的较重患者中,EGP-437疗效呈更好趋势。
- 截至第28天,EGP-437组眼压升高≥6 mm Hg事件13例次,少于PA 1%组的24例次。
核心结论
- 尽管两组临床应答率相似,EGP-437相对于醋酸泼尼松龙1%递减方案未达到统计非劣效。
- 数值趋势提示EGP-437眼压升高较少、总体疗效相似、在更严重疾病中可能更有效,需进一步研究。
研究设计与样本
- 前瞻性、随机、双盲、平行组、非劣效临床试验,共纳入193例活动性非感染性前节葡萄膜炎患者(前房细胞计数≥11个细胞)。
- 受试者随机接受第0天和第7天经离子导入递送的EGP-437,或每日自行使用醋酸泼尼松龙1%(第0-28天递减方案),并用安慰剂离子导入或滴眼液维持设盲。
主要发现
- 第14天,EGP-437组96例中32例(33.3%)与PA 1%组97例中32例(33.0%)前房细胞计数为零,差值0.34(95%CI -12.94至13.63,P=0.064)。
- 基线前房细胞计数>25的较重患者中,EGP-437疗效呈更好趋势。
- 两种治疗的安全性和耐受性均良好。
- 截至第28天,EGP-437组眼压升高≥6 mm Hg事件13例次,PA 1%组24例次。
关键数值与推荐
- 主要疗效终点为第14天前房细胞计数为零的受试者比例。
- 若EGP-437减PA 1%差值的置信区间下限小于-10%,则定义EGP-437非劣效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,数值趋势提示EGP-437眼压升高较少、总体疗效相似、在更严重疾病中可能更有效,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of dexamethasone phosphate ophthalmic solution (EGP-437) delivered by a transscleral iontophoresis delivery system (EyeGate II) compared to that of topical prednisolone acetate 1% (PA 1%) in subjects with noninfectious anterior uveitis. DESIGN: Prospective, randomized, double-masked, parallel group, noninferiority clinical trial. METHODS: A total of 193 subjects with active noninfectious anterior uveitis (anterior chamber [AC] cell count ≥11 cells) were randomized to EGP-437 delivered by iontophoresis (days 0 and 7) or self-administered PA 1% daily (tapered schedule, days 0-28). Masking was maintained with placebo iontophoresis or eye drops. The primary efficacy endpoint was the proportion of subjects with an AC cell count of zero on day 14. Noninferiority of EGP-437 was defined if the lower limit of the confidence interval (CI) for the difference (EGP-437 minus PA 1%) was less than -10%. RESULTS: At day 14, 32 of 96 EGP-437 subjects (33.3%) and 32 of 97 PA 1% subjects (33.0%) had an AC cell count of zero (difference, 0.34; 95% CI, -12.94 to 13.63; P = 0.064). Efficacy trended better with EGP-437 among patients with more severe baseline uveitis (AC cell count >25). Safety and tolerability were good with both treatments. EGP-437 subjects experienced fewer IOP elevations ≥6 mm Hg versus PA 1% subjects (13 vs 24 incidents, respectively, through day 28). CONCLUSIONS: Despite clinically similar response rates, statistical noninferiority of EGP-437 versus a tapered regimen of PA 1% was not achieved. Numerical trends suggesting fewer IOP elevations with EGP-437, similar efficacy overall, and possibly better efficacy in more severe disease warrant further study.
引用
- Sheppard J, Garg S, Lievens C, et al. Iontophoretic Dexamethasone Phosphate Compared to Topical Prednisolone Acetate 1% for Noninfectious Anterior Segment Uveitis. Am J Ophthalmol. 2019. PMID: 31726034. doi:10.1016/j.ajo.2019.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。